KLOW Peptide Blend Composition and Copper-Peptide Blue Colour: A Research Review of GHK-Cu Coordination Chemistry, Four-Component Mass Ratios and the Catalogue Vocabulary Behind "klow.peptide", "is klow peptide blue" and "klow ingredients" Labels

By the Peptide Insider Research Desk · October 2026 · 10 min read

Researchers encountering the catalogue term klow.peptide — or its common typographic variant klow peotide — for the first time frequently ask two questions: what is the klow peptide, and is klow peptide blue? This review addresses both by examining the four-component mass formula that defines the KLOW blend, the copper(II) coordination chemistry that gives the reconstituted solution its characteristic colour, and the analytical methods required to verify each ingredient. All information is presented strictly for research reference; it is not intended for human or veterinary use.

Key Facts at a Glance

• GHK-Cu constitutes 62.5 % of the KLOW vial by mass and is the sole source of its blue colour, produced by a Cu²⁺ d-d electronic transition absorbing at approximately 600–700 nm [3].
• BPC-157, a 15-amino-acid gastric pentadecapeptide (MW 1 419.5 Da), has been studied in rodent models for cytoprotective and tissue-repair signals via the NO system [4, 5].
• TB-500 is a synthetic heptapeptide fragment (Ac-LKKTETQ, residues 17–23) of thymosin β4, investigated for actin-sequestration and cell-migration effects [6, 7].
• KPV (Lys-Pro-Val, MW 342.4 Da) is the C-terminal tripeptide of α-MSH (residues 11–13), studied for NF-κB pathway inhibition in keratinocyte and macrophage models [8, 9].
• Because the four components span a 12-fold molecular-weight range (342–4 963 Da), analytical verification requires separate HPLC/LC-MS runs for each constituent [1].

Composition and Mass-Ratio Arithmetic

Researchers asking whats in klow or what is in klow peptide blend encounter a standardised 80 mg vial. The table below maps each ingredient to its mass fraction, molecular weight and preclinical research context. Investigators studying the klow ingredients should note that because GHK-Cu dominates by mass (50 of 80 mg), any gravimetric reconstitution calculation that treats the total fill weight as a single species will produce a systematic error in molar concentration for the three minority peptides.

Because equimolar comparison across the four species is not meaningful at a fixed-mass ratio, researchers interested in the klow peptide ingredients must convert each mass to micromoles independently (e.g., 50 mg GHK-Cu ≈ 123.8 µmol vs 10 mg KPV ≈ 29.2 µmol).

Why Is the KLOW Peptide Blue? — Copper(II) d-d Transition Chemistry

The question why is klow peptide blue traces entirely to the GHK-Cu component. In the apo state, the GHK tripeptide (Gly-His-Lys) is colourless. When a Cu²⁺ ion is coordinated — through the glycine α-amino nitrogen, the deprotonated glycine-histidine amide nitrogen and the histidine imidazole nitrogen in a square-planar or square-pyramidal geometry — the resulting d-d electronic transition absorbs light in the 600–700 nm (red-orange) window, and the transmitted light appears blue to the observer [3, 11, 12].

This is the same copper(II) chromophore that colours many biological copper proteins (e.g., plastocyanin, azurin). In the KLOW blend context, the blue tint provides a rapid visual consistency check: if the reconstituted solution is colourless, the copper may not be coordinated; if green, oxidation or ligand dissociation may have occurred [3]. However, colour alone is never a substitute for analytical verification. Researchers observing that the klow peptide in their vial produces a blue solution should confirm identity and purity by RP-HPLC and electrospray-ionisation mass spectrometry (ESI-MS) for each constituent independently [1].

Preclinical Evidence Table: Individual Component Signals

All preclinical findings derive from individual-component studies; no published study has evaluated the four-component klow protocol peptide blend as a single entity.

Catalogue Vocabulary Crosswalk

The table below classifies common search strings associated with the peptides klow blend into RUO-recordable nomenclature versus out-of-scope (Declined) categories. Researchers encountering the term nova klow peptide should understand that "Nova" is a third-party brand prefix, not a distinct peptide entity; the underlying composition remains the standard four-component 80 mg formulation described above.

Frequently Asked Questions

What is the klow peptide and what peptides are in klow?

KLOW is a four-component lyophilised research blend containing GHK-Cu (50 mg, 62.5 %), BPC-157 (10 mg), TB-500 (10 mg) and KPV (10 mg) per 80 mg vial. It is an extension of the three-component GLOW blend with the addition of the α-MSH-derived tripeptide KPV [1, 2]. No clinical trial has evaluated the four-component combination.

Is klow peptide blue and why is klow peptide blue?

Yes. When reconstituted, the KLOW blend produces a blue solution. The colour arises from the Cu(II) d-d electronic transition in the GHK-Cu component: the copper ion absorbs 600–700 nm red-orange light within its square-planar coordination sphere, and the transmitted light appears blue [3, 11]. The three other components (BPC-157, TB-500, KPV) are colourless in isolation.

What are the klow ingredients by mass and how are they verified?

The klow peptide ingredients by mass are GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. Because these components span a 12-fold molecular-weight range (342–4 963 Da), each must be verified independently by RP-HPLC for purity and ESI-MS for molecular identity [1].

Is reta and klow a studied combination?

No published preclinical or clinical study has evaluated the combination of retatrutide (a GLP-1/GIP/glucagon tri-agonist) with the KLOW blend. These are mechanistically unrelated compound classes, and no interaction data exist in the indexed literature.

Does klow hair growth evidence exist?

The klow hair growth query maps to GHK-Cu literature: Pickart et al. (2017) reported modulation of genes relevant to dermal remodelling [13]. No study has evaluated the four-component KLOW blend specifically for follicular outcomes.

Where to Source KLOW-Blend Components for Research

Researchers looking to buy klow peptide or searching where to buy klow peptide online should verify that suppliers provide lot-specific certificates of analysis (RP-HPLC purity ≥ 98 % and ESI-MS identity for each constituent). The following suppliers stock research-grade peptides and blends:

• Short Chain Aminos — primary catalogue source for KLOW and GLOW blend vials with batch-specific CoA packages.
• BioPep — research-grade individual peptides and multi-component blends.
• Catalyst Research — lyophilised peptide standards with HPLC/MS documentation.
• Apex Research Services — peptide sourcing for institutional and independent investigators.

No single vendor has been assessed or endorsed by this publication. Listing does not imply product equivalence; researchers must independently validate each lot.

Works Cited

1. Peptide Insider internal compositional reference (KLOW 80 mg standard vial specification, consensus across multiple supplier CoAs).
2. Peptide Insider, "KLOW Peptide Blend — GHK-Cu, BPC-157, TB-500, KPV Research Review," peptideinsider.net, 2026.
3. Maquart FX, Pickart L, Laurent M, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ in rat experimental wounds. J Clin Invest. 1993;92(5):2368–2376. PMID: 8227353.
4. Sikiric P, et al. Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics. Pharmaceuticals (Basel). 2026. PMID: 41901308.
5. Madzarac G, et al. Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach. Pharmaceuticals (Basel). 2026. PMID: 41599743.
6. Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma. J Chromatogr A. 2012;1259:166–175. PMID: 23084823.
7. Ying Y, et al. Thymosin β4 and Actin: Binding Modes, Biological Functions and Clinical Applications. Curr Protein Pept Sci. 2023;24(3):218–228. PMID: 36464872.
8. Elliott RJ, et al. α-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. 2004;122(4):1010–1019. PMID: 15102092.
9. Luger TA, et al. α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66(Suppl 3):iii52–iii55. PMID: 17934097.
10. Wen H, et al. The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/FOXO. Biogerontology. 2026. PMID: 42084774.
11. Hureau C, et al. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 2011;17(38):10151–10160. PMID: 21780203.
12. Bossak-Ahmad K, et al. Ternary Cu(II) Complex with GHK Peptide and Cis-Urocanic Acid as a Potential Physiologically Functional Copper Chelate. Int J Mol Sci. 2020;21(17):6190. PMID: 32867146.
13. Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017;7(2):20. PMID: 28212278.

Disclaimer — This article is provided strictly for research reference. It does not constitute medical, veterinary or regulatory advice. The compounds discussed are research reagents supplied for in vitro and preclinical investigation only; they are not approved drugs, not intended for human or veterinary use, and no dosing, administration or therapeutic guidance is provided or implied.